Ravi Salgia, MD, PhD, Professor of Medicine, Pathology and Dermatology, Director, Chest Oncology and Thoracic Oncology Research Program, Vice Chair, Translational Research, Center for Advanced Medicine, The University of Chicago Medicine, discusses crizotinib and its resistance.

While he is excited about the therapeutic responses to crizotinib, he said that there is concern regarding the growing frequency of progression past crizotinib. New therapeutic plans are in development testing small molecule inhibitors and HSP90 inhibitors in crizotinib-resistant patients.

свернуть